Chase Sun(SZ:300026) Guohai Securities·2025-09-09 11:32Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [1][2]. Core Views - The company's short-term performance is under pressure due to the impact of centralized procurement on traditional Chinese medicine formula granules, while the "Xuebijing" injection shows steady growth [2]. - The implementation of national standards for formula granules is expected to enhance long-term growth prospects for the company [2]. Financial Performance Summary - In the first half of 2025, the company reported revenue of 1.232 billion yuan for formula granules (down 5.75% year-on-year), 467 million yuan for "Xuebijing" injection (up 2.88% year-on-year), and 433 million yuan for the smart supply chain (down 3.92% year-on-year) [2]. - The company forecasts net profits attributable to shareholders of 243 million yuan in 2025, 262 million yuan in 2026, and 352 million yuan in 2027, with corresponding P/E ratios of 48, 45, and 33 times [2][3]. Revenue and Profit Forecast - Projected revenues for the company are 5.464 billion yuan in 2025, 5.693 billion yuan in 2026, and 5.959 billion yuan in 2027, reflecting a decline of 6% in 2025 followed by growth of 4% and 5% in the subsequent years [3][4]. - The expected profit growth rates show a significant rebound, with a forecasted increase of 1,031% in 2025, followed by 8% in 2026 and 34% in 2027 [3][4]. Market Position and Valuation - As of September 8, 2025, the company's stock price is 3.91 yuan, with a total market capitalization of approximately 11.746 billion yuan [1][4]. - The report highlights that the number of national standards for formula granules is gradually increasing, which is expected to improve the competitive position of the company in the market [2].